{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:08:45Z","timestamp":1767928125882,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Gaucher disease (GD) is a lysosomal storage disorder characterized by glucosylceramide accumulation, which may lead to liver fibrosis and cirrhosis. Enzyme replacement therapy (ERT) could reverse fibrosis. This study aimed to assess liver and spleen stiffness and hepatic steatosis in adult type 1 GD patients receiving ERT, using transient elastography (TE) (Fibroscan\n                      <jats:bold>\u00ae<\/jats:bold>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Twenty-five type 1 GD patients were evaluated pre- and post-ERT. TE findings of GD patients on ERT were compared cross-sectionally with a control group. Liver fibrosis was defined as\u2009\u22657\u00a0kPa, and significant steatosis was defined as a Controlled Attenuation Parameter (CAP) measurement\u2009\u2265\u2009250\u00a0dB\/min. Associations between TE findings and clinical, metabolic, genetic characteristics, FIB4 (fibrosis 4) and APRI (AST to platelet ratio index) scores, were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-six percent of GD patients were female, with a median disease duration of 13\u00a0years. Post-ERT, body weight (57.3 vs. 63.6\u00a0kg,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), body mass index (22 vs. 23.8\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and metabolic syndrome (MetS) prevalence (12% vs. 40%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016) were increased. Hepatic steatosis was more frequent (32% vs. 16%). Liver fibrosis was present in 44% of GD patients, but in none of the controls. GD patients exhibited significantly higher liver (6.6 vs. 3.7\u00a0kPa;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and spleen stiffness (17.6 vs. 11.1;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032). Liver fibrosis was positively correlated with ALT, GGT, ferritin levels, disease duration, and delayed initiation of ERT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although ERT improved fibrosis-related parameters, GD patients demonstrated higher liver and spleen stiffness. Elevated ferritin levels, longer disease duration, and delayed initiation of ERT were associated with liver fibrosis. Additionally, increased metabolic syndrome prevalence post-ERT may contribute to the development of hepatic steatosis in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03847-5","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:46:40Z","timestamp":1767865600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of liver and spleen stiffness and hepatic steatosis by transient elastography (Fibroscan\u00ae) in type 1 Gaucher disease: a single center case\u2013control cohort study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-7326","authenticated-orcid":false,"given":"Ummu","family":"Mutlu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilger","family":"Cavus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hulya","family":"Hacisahinogullari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsah","family":"Yenidunya Yalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Soyluk Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse","family":"Kubat Uzum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadir","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Tanakol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"3847_CR1","unstructured":"Beutler E. Gaucher disease. The metabolic and molecular bases of inherited disease. 2001:3635\u20133668."},{"key":"3847_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151\u20136.","journal-title":"Hum Genet"},{"key":"3847_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bcmd.2016.10.001","volume":"68","author":"T Adar","year":"2018","unstructured":"Adar T, Ilan Y, Elstein D, Zimran A. Liver involvement in Gaucher disease - review and clinical approach. Blood Cells Mol Dis. 2018;68:66\u201373. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.001.","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"3847_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.dld.2020.01.004","volume":"52","author":"F Carubbi","year":"2020","unstructured":"Carubbi F, Cappellini MD, Fargion S, Fracanzani AL, Nascimbeni F. Liver involvement in Gaucher disease: a practical review for the hepatologist and the gastroenterologist. Dig Liver Dis. 2020;52(4):368\u201373. https:\/\/doi.org\/10.1016\/j.dld.2020.01.004.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3847_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0016-5085(81)90202-X","volume":"80","author":"SP James","year":"1981","unstructured":"James SP, Stromeyer FW, Chang C, Barranger JA. Liver abnormalities in patients with Gaucher\u2019s disease. Gastroenterology. 1981;80(1):126\u201333. https:\/\/doi.org\/10.1016\/0016-5085(81)90202-X.","journal-title":"Gastroenterology"},{"key":"3847_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","volume":"41","author":"M Regenboog","year":"2018","unstructured":"Regenboog M, van Dussen L, Verheij J, et al. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis. 2018;41:819\u201327.","journal-title":"J Inherit Metab Dis"},{"key":"3847_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bcmd.2018.10.004","volume":"74","author":"RT Starosta","year":"2019","unstructured":"Starosta RT, Vairo FPE, Dornelles AD, Cerski CTS, \u00c1lvares-da-Silva MR, Schwartz IVD. Hepatocellular carcinoma in Gaucher disease: reinforcing the proposed guidelines. Blood Cells Mol Dis. 2019;74:34\u20136.","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"3847_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/flgastro-2021-102064","volume":"13","author":"AJ Archer","year":"2022","unstructured":"Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KW. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Front Gastroenterol. 2022;13(5):436\u20139. https:\/\/doi.org\/10.1136\/flgastro-2021-102064.","journal-title":"Front Gastroenterol"},{"key":"3847_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bcmd.2016.10.012","volume":"68","author":"F Nascimbeni","year":"2018","unstructured":"Nascimbeni F, Dalla Salda A, Carubbi F. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2018;68:74\u201380. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.012.","journal-title":"Blood Cells Mol Dis"},{"key":"3847_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bcmd.2016.12.010","volume":"68","author":"M Webb","year":"2018","unstructured":"Webb M, Zimran A, Dinur T, et al. Are transient and shear wave elastography useful tools in Gaucher disease? Blood Cells Mol Dis. 2018;68:143\u20137. https:\/\/doi.org\/10.1016\/j.bcmd.2016.12.010.","journal-title":"Blood Cells Mol Dis"},{"issue":"1\u20132","key":"3847_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymgme.2018.08.004","volume":"125","author":"F Nascimbeni","year":"2018","unstructured":"Nascimbeni F, Cassinerio E, Dalla Salda A, et al. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Mol Genet Metab. 2018;125(1\u20132):64\u201372. https:\/\/doi.org\/10.1016\/j.ymgme.2018.08.004.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"3847_CR12","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/liv.14640","volume":"40","author":"F Nascimbeni","year":"2020","unstructured":"Nascimbeni F, Lugari S, Cassinerio E, et al. Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. Liver Int. 2020;40(12):3061\u201370. https:\/\/doi.org\/10.1111\/liv.14640.","journal-title":"Liver Int"},{"issue":"2","key":"3847_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ymgme.2019.10.013","volume":"129","author":"P Lipi\u0144ski","year":"2020","unstructured":"Lipi\u0144ski P, Szyma\u0144ska-Ro\u017cek P, Socha P, Tylki-Szyma\u0144ska A. Controlled attenuation parameter and liver stiffness measurements using transient elastography by FibroScan in Gaucher disease. Mol Genet Metab. 2020;129(2):125\u201331. https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.013.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3847_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pedneo.2018.05.002","volume":"60","author":"CY Chin","year":"2019","unstructured":"Chin CY, Hsu CT, Lee CS, Chien YH, Wu JF. Monitoring of liver stiffness by transient elastography during the treatment of Gaucher disease. Pediatr Neonatol. 2019;60(2):221\u20133. https:\/\/doi.org\/10.1016\/j.pedneo.2018.05.002.","journal-title":"Pediatr Neonatol"},{"issue":"2","key":"3847_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ymgme.2020.03.006","volume":"130","author":"A Lollert","year":"2020","unstructured":"Lollert A, Hoffmann C, Lache M, et al. Acoustic radiation force impulse point shear wave elastography of the liver and spleen in patients with Gaucher disease type 1: correlations with clinical data and markers of disease severity. Mol Genet Metab. 2020;130(2):140\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2020.03.006.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3847_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109010","volume":"144","author":"RT Starosta","year":"2025","unstructured":"Starosta RT, Ferraro LC, de Mattos GP, et al. Predicting liver fibrosis in Gaucher disease: investigation of contributors and development of a clinically applicable Gaucher liver fibrosis score. Mol Genet Metab. 2025;144(2): 109010. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109010.","journal-title":"Mol Genet Metab"},{"key":"3847_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/v15081730","author":"L Rinaldi","year":"2023","unstructured":"Rinaldi L, Giorgione C, Mormone A, et al. Non-invasive measurement of hepatic fibrosis by transient elastography: a narrative review. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15081730.","journal-title":"Viruses"},{"key":"3847_CR18","doi-asserted-by":"crossref","unstructured":"Liver EAftSot. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of hepatology. 2015;63(1):237\u2013264.","DOI":"10.1016\/j.jhep.2015.04.006"},{"issue":"11","key":"3847_CR19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825\u201335. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2010.07.005.","journal-title":"Ultrasound Med Biol"},{"issue":"3","key":"3847_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057507","volume":"8","author":"AE Bohte","year":"2013","unstructured":"Bohte AE, van Dussen L, Akkerman EM, et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS ONE. 2013;8(3): e57507. https:\/\/doi.org\/10.1371\/journal.pone.0057507.","journal-title":"PLoS ONE"},{"issue":"16","key":"3847_CR21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/circulationaha.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640\u20135. https:\/\/doi.org\/10.1161\/circulationaha.109.192644.","journal-title":"Circulation"},{"issue":"2","key":"3847_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2011.02.010","volume":"55","author":"PC Adams","year":"2011","unstructured":"Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol. 2011;55(2):453\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2011.02.010.","journal-title":"J Hepatol"},{"issue":"2","key":"3847_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326. https:\/\/doi.org\/10.1053\/jhep.2003.50346.","journal-title":"Hepatology"},{"issue":"6","key":"3847_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325. https:\/\/doi.org\/10.1002\/hep.21178.","journal-title":"Hepatology"},{"issue":"8","key":"3847_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/qjmed\/hcu045","volume":"107","author":"AG Stack","year":"2014","unstructured":"Stack AG, Mutwali AI, Nguyen HT, Cronin CJ, Casserly LF, Ferguson J. Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population. QJM. 2014;107(8):623\u201333. https:\/\/doi.org\/10.1093\/qjmed\/hcu045.","journal-title":"QJM"},{"key":"3847_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-4614-0650-1_7","volume":"721","author":"JM Aerts","year":"2011","unstructured":"Aerts JM, Boot RG, van Eijk M, et al. Glycosphingolipids and insulin resistance. Adv Exp Med Biol. 2011;721:99\u2013119. https:\/\/doi.org\/10.1007\/978-1-4614-0650-1_7.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"3847_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","volume":"389","author":"K Ghauharali-van der Vlugt","year":"2008","unstructured":"Ghauharali-van der Vlugt K, Langeveld M, Poppema A, et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta. 2008;389(12):109\u201313. https:\/\/doi.org\/10.1016\/j.cca.2007.12.001.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"3847_CR28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","volume":"38","author":"DJ Barton","year":"1989","unstructured":"Barton DJ, Ludman MD, Benkov K, Grabowski GA, LeLeiko NS. Resting energy expenditure in Gaucher\u2019s disease type 1: effect of Gaucher\u2019s cell burden on energy requirements. Metabolism. 1989;38(12):1238\u201343. https:\/\/doi.org\/10.1016\/0026-0495(89)90165-0.","journal-title":"Metabolism"},{"issue":"1","key":"3847_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1743-7075-10-34","volume":"10","author":"D Doneda","year":"2013","unstructured":"Doneda D, Netto CB, Moulin CC, Schwartz IV. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond). 2013;10(1):34. https:\/\/doi.org\/10.1186\/1743-7075-10-34.","journal-title":"Nutr Metab (Lond)"},{"issue":"11","key":"3847_CR30","doi-asserted-by":"publisher","first-page":"G1102","DOI":"10.1152\/ajpgi.00095.2016","volume":"310","author":"Y Ilan","year":"2016","unstructured":"Ilan Y. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1102\u201317. https:\/\/doi.org\/10.1152\/ajpgi.00095.2016.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"3847_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3904\/kjim.2020.635","volume":"37","author":"HW Yoo","year":"2022","unstructured":"Yoo HW, Kim SG, Jang JY, et al. Two-dimensional shear wave elastography for assessing liver fibrosis in patients with chronic liver disease: a prospective cohort study. Korean J Intern Med. 2022;37(2):285\u201393. https:\/\/doi.org\/10.3904\/kjim.2020.635.","journal-title":"Korean J Intern Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03847-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:02:34Z","timestamp":1767909754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-03847-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3847"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03847-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed following the Declaration of Helsinki recommendations, and the Clinical Ethics Committee of Istanbul Faculty of Medicine approved the study. All patients and the controls were informed about the study, and informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no competing interests to declare relevant to this article\u2019s content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Each author confirms that this manuscript has been prepared and sent with his\/her approval. Authors acknowledge that this paper\u2019s copyright is transferred to the journal's property.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"6"}}